You are here: Industry Insights > BMS

News List

COVID-19: ‘Army’ of volunteers join NHS as BMS postpones new study starts pharmatimes
March 27, 2020
After the government put out a “call to arms” for new NHS volunteers to help vulnerable people to stay safe and at home, a “staggering” 405,724 people ...
Chinese ABRAXANE® supply expected to be disrupted europeanpharmaceuticalreview
March 27, 2020
The marketing agent for China, BeiGene, announced the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE.
BeiGene Announces Supply Update for ABRAXANE® in China BeiGene
March 26, 2020
NMPA has suspended the importation, sales and use of ABRAXANE in China supplied by Celgene Corporation, a Bristol Myers Squibb (BMS) company; As the marketing agent for ABRAXANE in China, BeiGene is working with BMS to restore supply in China.
BMS secures FDA priority review for NSCLC treatment combination pharmaceutical-technology
January 17, 2020
Bristol-Myers Squibb Company (BMS) has secured the US Food and Drug Administration (FDA) priority review for a drug combination to treat metastatic or recurrent non-small cell lung cancer (NSCLC).
BMS’ Orencia gets breakthrough status in US to prevent GvHD pharmaceutical-technology
December 09, 2019
Bristol-Myers Squibb (BMS) has received breakthrough device designation for its Orencia (abatacept) drug to prevent moderate to severe acute graft-versus-host disease (GvHD).
PTC Therapeutics Expands in New Jersey contractpharma
August 06, 2019
Secures BMS biologics facility to support gene therapy production.
Nektar Therapeutics, BMS Receive Breakthrough Therapy Designation contractpharma
August 02, 2019
Bempegaldesleukin in combination with Bristol-Myers Squibb's Opdivo aims to treat patients with untreated advanced melanoma.
Can BMS parlay its surprise 'win and a miss' in first-line lung cancer into a net gain? fiercepharma
July 28, 2019
If you thought you knew what was coming in Bristol-Myers Squibb’s CheckMate-227 trial, forget it.
BMS’ Opdivo fails to meet primary endpoint in NSCLC pharmaceutical-technology
July 26, 2019
Bristol-Myers Squibb (BMS) has announced that its immunotherapy Opvido (nivolumab) plus chemotherapy failed to meet its primary endpoint of overall survival (OS) in the Phase III CheckMate-227 trial of patients with first-line non-squamous non-small cell
Bayer, BMS, Ono to Collaborate on Colorectal Cancer Treatments contractpharma
July 19, 2019
Aims to evaluate the combination of Bayer's Stivarga and BMS / Ono's Opdivo in patients with MSS mCRC.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 15 16 Next page